ArticleBMC cancer2026
Prognostic value of tertiary lymphoid structures in high-risk esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTertiary lymphoid structures (TLSs) are implicated in anti-tumor immunity. However, their prognostic value in esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemoimmunotherapy (NCI) remains unestablished, particularly in high-risk subgroups.
methodsWe retrospectively analyzed a cohort of 186 ESCC patients who underwent curative-intent surgery after NCI. TLS density, maturity, and spatial distribution were evaluated. Prognostic models were developed using LASSO and multivariable Cox regression. Spatial proteomic profiling (GeoMx DSP) and immunohistochemistry were performed to characterize TLS-associated immune landscapes in high-risk stage III patients.
resultsHigh overall TLS (oTLS) density and the presence of secondary follicle-like TLSs (SFTs) were independently associated with superior overall survival (OS) and disease-free survival (DFS). Notably, in patients with poor pathological response, lymph node metastasis, or advanced-stage disease, those with robust TLS signatures had survival outcomes that were not significantly different from those of lower-risk patients who lacked favorable TLS features. Furthermore, TLSs in the peritumoral compartment demonstrated significant prognostic value. A TLS-incorporated nomogram and a simplified TLS-based risk-scoring system were developed, which demonstrated superior predictive accuracy over models based on traditional clinicopathological factors alone. Spatial proteomic and immunohistochemical analyses revealed that TLS-high tumors exhibited enrichment of CD38⁺ plasma cells surrounding TLSs.
conclusionTLS characteristics are potent, independent prognostic determinants in ESCC after NCI, capable of mitigating risks associated with adverse clinicopathological features. The developed models provide practical tools for personalized risk stratification, with mechanistic insights linking TLSs to plasma cell-mediated immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.